On August 18, 2023 Medivir reported Continued strong momentum and promising signs of patient benefit in the combination study with fostrox and Lenvima (Press release, Medivir, AUG 18, 2023, View Source;interim-report-january–june-2023-301904356.html [SID1234634506]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
April – June
Financial summary for the quarter
Net turnover amounted to SEK 2.0 (0.5) million.
The loss before interest, tax, depreciation and amortization (EBITDA) amounted to SEK -26.3
(-21.5) million. Basic and diluted earnings per share amounted to SEK -0.47 (-0.42) and SEK -0.47 (-0.42) respectively.
Cash flow from operating activities amounted to SEK -17.9 (-17.6) million.
Cash and cash equivalents at the end of the period amounted to SEK 82.8 (162.8) million.
Significant events during the quarter
In April, new data were presented showing synergistic anti-tumor effect of fostrox in triple combination with anti-PD1 and Lenvima in non-clinical tumor models.
Medivir’s patent application for fostrox was approved by the patent authority in China.
January – June
Financial summary for the period
Net turnover amounted to SEK 2.4 (1.0) million.
The loss before interest, tax, depreciation and amortization (EBITDA) amounted to SEK -45.2
(-52.9) million. Basic and diluted earnings per share amounted to SEK -0.81 (-1.00) and SEK -0.81 (-1.00) respectively.
Cash flow from operating activities amounted to SEK -34.1 (-57.5) million.
Cash and cash equivalents at the end of the period amounted to SEK 82.8 (162.8) million.
Events after the end of the period
In August, Medivir’s Scientific Advisory Council was formed, consisting of five world-leading experts in liver cancer.
In August, the 15th patient was included in the phase 2a study with fostrox in combination with Lenvima, which shows promising tumor control and good tolerability.
Conference call for investors, analysts and the media
The Interim Report January – June 2023 will be presented by Medivir’s CEO, Jens Lindberg.
Time: Friday, August 18, 2023, at 14.00 (CET).
For dial-in numbers to the conference call, please see information on the website; www.medivir.com/investors/calendar
The conference call will also be streamed via a link on the website: www.medivir.com
The presentation will be available on Medivir’s website after completion of the conference.